Business Context and Reporting Period
This Form 8-K Current Report was filed by Altimmune, Inc. on October 3, 2025, covering events occurring on October 1, 2025. The filing addresses Item 5.02 regarding the departure of a senior officer and the appointment of a successor.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation and personnel changes.
Material Changes
- Leadership Transition: Dr. Scott Harris stepped down as Chief Medical Officer (CMO) effective October 1, 2025.
- New Appointment: Christophe Arbet-Engels, MD, PhD, joined as the new CMO effective October 1, 2025.
- Role Change: Dr. Harris will serve as a Senior Strategic Advisor through his previously announced Separation Date of February 28, 2026.
Guidance, Outlook, and Compensation Details
The filing details a Transitional Services and Release Agreement between the Company and Dr. Harris. Key terms include:
- Compensation: Dr. Harris will continue to receive his current salary and benefits during the transition period.
- Equity: Continued vesting of all outstanding equity awards through the Separation Date.
- Option Exercise: An extension of the exercise period for vested stock options until the 12-month anniversary of the Separation Date.
- Bonus Eligibility: Dr. Harris remains eligible for a full cash bonus for fiscal year 2025, subject to criteria achievement and compliance with the agreement.
- Conditions: Payments and benefits are contingent upon Dr. Harris not revoking a general release of claims and adhering to restrictive covenants.
The filing does not contain forward-looking guidance on financial performance or clinical trial outcomes.
Investor Verification Checklist
- Verify the full text of the Transitional Services and Release Agreement when filed in the next Form 10-Q.
- Confirm the specific bonus criteria for fiscal year 2025 to assess the likelihood of the payout.
- Monitor the integration of the new CMO and the timeline for the transition of duties.
- Review the impact of the leadership change on ongoing clinical programs and regulatory interactions.